GSK, Pfizer And Shionogi's ViiV Healthcare Expands On Real-World Data Supporting Use Of Long-Acting Therapies In Diverse Patient Populations At HIV Glasgow
GSK, Pfizer And Shionogi's ViiV Healthcare Expands On Real-World Data Supporting Use Of Long-Acting Therapies In Diverse Patient Populations At HIV Glasgow
高盛、輝瑞和塞諾基的威靈製藥公司在HIV格拉斯哥擴展現實世界數據，支持多樣化患者群體使用長效療法
- New analyses highlight use of long-acting injectable Vocabria + Rekambys (cabotegravir + rilpivirine LA) in clinical trial and real-world populations, and the economic and public health impact of Apretude (cabotegravir LA for PrEP)
- Findings from the DOLCE study explore the efficacy of 2-drug regimen Dovato (dolutegravir/lamivudine) compared to three-drug regimen in people with advanced HIV with CD4 count ≤ 200 cells/mm3
- Additional key abstracts include findings from pipeline bNAb asset, VH3810109, as a potential approach to treating HIV
- 最新分析突出了長效注射劑Vocabria + Rekambys（卡博替格韋 + 利比替定LA）在臨床試驗和真實世界人群中的應用，以及Apretude（適用於PrEP的卡博替格韋LA）的經濟和公共衛生影響。
- DOLCE研究結果表明，與三藥療法相比，2藥療法Dovato（度洛替尼/拉米夫定）在CD4計數≤ 200 細胞/mm3的晚期HIV患者中的療效。
- 其他關鍵摘要包括作爲治療HIV的潛在方法的管線bNAb資產VH3810109的研究結果。
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, will share new data from its industry-leading HIV treatment and prevention portfolio and pipeline at HIV Glasgow 2024, being held in Glasgow, Scotland from 10 – 13 November 2024. Spanning 42 abstracts, the data showcases long-acting and two-drug regimens as care options for diverse populations in the face of a continuing HIV epidemic.
由全球專門從事HIV公司ViiV Healthcare（主要由GSK擁有，輝瑞和Shionogi是股東）分享其領先行業的HIV治療和預防組合以及管線的最新數據，將於2024年11月10日至13日在蘇格蘭的格拉斯哥舉行的HIV Glasgow 2024會議上展示。這42個摘要涵蓋了長效和兩藥療法作爲面對持續HIV流行的不同人群的護理選擇。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間